Gland Pharma Q4 net profit slips 3% as US sales moderate; focus shifts to complex injectables, CDMO growth

Gland Pharma

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Gland Pharma, a leading injectable-focused pharmaceutical company, on Tuesday reported a 3% year-on-year (YoY) decline in net profit for the quarter ended March 31, 2025, as softer US sales and ongoing turnaround efforts at its European unit Cenexi weighed on performance. Consolidated revenue fell 7% YoY to Rs 1,425 crore, while EBITDA declined 3% to Rs 3,47.5 crore. Net profit stood at Rs 186.5 crore, with PAT margins holding steady at 13%.

For the full fiscal year, revenue was marginally lower at Rs 5,616.5 crore, while net profit dropped 10% to Rs 698.5 crore. The company declared a final dividend of Rs 18 per share for FY25.

“FY25 was a year of strategic realignment and investment in future growth,” said Executive Chairman Srinivas Sadu. “We strengthened our core in manufacturing, quality, and R&D, while expanding into biologics and complex injectables.”

-The base business EBITDA margin improved to 38% in Q4, driven by high-margin launches and volume traction in the US.

-US market contributed 54% of FY25 revenue dropped 10% YoY to Rs 792 crore in Q4FY25; four new products launched in Q4, including Latanoprost and Midazolam RTU bags.

-Cenexi, the French CDMO acquired in FY24, posted 8% YoY revenue growth in Q4 but remained EBITDA-negative. A turnaround is targeted by Q3 FY26.

-R&D spend rose to ₹503 crore in Q4 (4.9% of revenue), with 31 product launches and 32 ANDA approvals in FY25.

-GLP-1 franchise scaled up with the launch of Liraglutide and capacity expansion plans to 140 million units.

CEO Shyamakant Giri said the company is focused on accelerating growth in India and Rest of World (RoW) markets, while deepening its US portfolio and enhancing cost efficiency. Gland is also investing in biologics CDMO capabilities through partnerships with Dr. Reddy’s and Henlius, with revenue contribution expected from FY26.

Cenexi’s Q4 revenue rose 8% YoY to ₹3,917 crore, aided by growth at its Belgium and Normandy sites. However, EBITDA remained negative at -₹479 crore. A new ampoule line and ophthalmic gel production are expected to boost capacity and margins in FY26.

Gland’s in-house complex injectable pipeline includes 19 products with a US market opportunity of $6.5 billion. The company has filed nine ANDAs and launched six products from this portfolio. A co-development pipeline of 15 products is also underway, with commercialization expected from FY27.